WallStSmart

Harrow Health Inc (HROW)vsMerck & Company Inc (MRK)

VS
⚡

Smart Verdict

WallStSmart Research — data-driven comparison

Merck & Company Inc generates 24055% more annual revenue ($66.57B vs $275.59M). MRK leads profitability with a 4.8% profit margin vs -13.5%. MRK earns a higher WallStSmart Score of 36/100 (F).

HROW

Avoid

23

out of 100

Grade: F

Growth: 6.0Profit: 2.0Value: 5.0Quality: 4.5
Piotroski: 4/9Altman Z: 0.76

MRK

Hold

36

out of 100

Grade: F

Growth: 4.0Profit: 4.5Value: 2.0Quality: 5.0
Piotroski: 3/9Altman Z: 2.27
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for HROW.

MRKSignificantly Overvalued (-78.2%)

Margin of Safety

-78.2%

Fair Value

$83.04

Current Price

$148.78

$65.74 premium

UndervaluedFair: $83.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

HROW0 strengths · Avg: 0/10

No standout strengths identified

MRK2 strengths · Avg: 9.0/10
Market CapQuality
$365.34B10/10

Mega-cap, among the largest globally

Free Cash FlowQuality
$4.48B8/10

Generating 4.5B in free cash flow

Areas to Watch

HROW4 concerns · Avg: 2.3/10
Market CapQuality
$1.41B3/10

Smaller company, higher risk/reward

Price/BookValuation
80.7x2/10

Trading at 80.7x book value

Return on EquityProfitability
-35.4%2/10

ROE of -35.4% — below average capital efficiency

EPS GrowthGrowth
-10.3%2/10

Earnings declined 10.3%

MRK4 concerns · Avg: 3.3/10
Price/BookValuation
8.8x4/10

Trading at 8.8x book value

Return on EquityProfitability
7.6%3/10

ROE of 7.6% — below average capital efficiency

Profit MarginProfitability
4.8%3/10

4.8% margin — thin

Debt/EquityHealth
1.293/10

Elevated debt levels

Comparative Analysis Report

WallStSmart Research

Bull Case : HROW

Revenue growth of 10.9% demonstrates continued momentum.

Bull Case : MRK

The strongest argument for MRK centers on Market Cap, Free Cash Flow.

Bear Case : HROW

The primary concerns for HROW are Market Cap, Price/Book, Return on Equity. Debt-to-equity of 19.79 is elevated, increasing financial risk.

Bear Case : MRK

The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 120.4x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.

Key Dynamics to Monitor

HROW profiles as a turnaround stock while MRK is a value play — different risk/reward profiles.

HROW carries more volatility with a beta of 0.24 — expect wider price swings.

HROW is growing revenue faster at 10.9% — sustainability is the question.

MRK generates stronger free cash flow (4.5B), providing more financial flexibility.

Bottom Line

MRK scores higher overall (36/100 vs 23/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Harrow Health Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Harrow Health, Inc. is an ophthalmology-focused healthcare company. The company is headquartered in San Diego, California.

Merck & Company Inc

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.

Visit Website →

Want to dig deeper into these stocks?